vs
Side-by-side financial comparison of GLADSTONE LAND Corp (LAND) and RHYTHM PHARMACEUTICALS, INC. (RYTM). Click either name above to swap in a different company.
RHYTHM PHARMACEUTICALS, INC. is the larger business by last-quarter revenue ($60.1M vs $16.6M, roughly 3.6× GLADSTONE LAND Corp). On growth, RHYTHM PHARMACEUTICALS, INC. posted the faster year-over-year revenue change (83.8% vs -1.5%). Over the past eight quarters, RHYTHM PHARMACEUTICALS, INC.'s revenue compounded faster (43.8% CAGR vs -11.8%).
Hongkong Land (HKL) is a property investment, management and development group with commercial and residential property interests across Asia. It owns and manages some 850,000 sq. m. of office and retail property in Asia, principally in Hong Kong and Singapore. Its Hong Kong portfolio represents some 450,000 sq. m. of commercial property, making it the single largest landlord in Central, Hong Kong. In Singapore it has 165,000 sq. m. of office space mainly held through joint ventures. While it...
Rhythm Pharmaceuticals is a biopharmaceutical firm focused on developing and commercializing targeted therapies for rare genetic disorders causing severe unmanageable obesity, including POMC deficiency, LEPR deficiency, and Bardet-Biedl syndrome. It serves patients in North America and Europe who lack effective standard treatments for their chronic life-altering conditions.
LAND vs RYTM — Head-to-Head
Income Statement — Q1 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $16.6M | $60.1M |
| Net Profit | — | $-55.6M |
| Gross Margin | — | 88.1% |
| Operating Margin | 200.3% | -87.1% |
| Net Margin | — | -92.6% |
| Revenue YoY | -1.5% | 83.8% |
| Net Profit YoY | — | — |
| EPS (diluted) | — | $-0.83 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $16.6M | $60.1M | ||
| Q4 25 | $41.5M | $57.3M | ||
| Q3 25 | $17.8M | $51.3M | ||
| Q2 25 | $12.3M | $48.5M | ||
| Q1 25 | $16.8M | $32.7M | ||
| Q4 24 | $21.1M | $41.8M | ||
| Q3 24 | $22.6M | $33.3M | ||
| Q2 24 | $21.3M | $29.1M |
| Q1 26 | — | $-55.6M | ||
| Q4 25 | $4.2M | $-47.5M | ||
| Q3 25 | $2.1M | $-52.9M | ||
| Q2 25 | $-7.9M | $-46.6M | ||
| Q1 25 | $15.1M | $-49.5M | ||
| Q4 24 | $540.0K | $-43.3M | ||
| Q3 24 | $6.0K | $-43.6M | ||
| Q2 24 | $-823.0K | $-32.3M |
| Q1 26 | — | 88.1% | ||
| Q4 25 | — | 91.6% | ||
| Q3 25 | — | 89.3% | ||
| Q2 25 | — | 88.6% | ||
| Q1 25 | — | 88.8% | ||
| Q4 24 | — | 90.9% | ||
| Q3 24 | — | 88.5% | ||
| Q2 24 | — | 89.9% |
| Q1 26 | 200.3% | -87.1% | ||
| Q4 25 | — | -82.2% | ||
| Q3 25 | — | -102.6% | ||
| Q2 25 | — | -93.4% | ||
| Q1 25 | — | -143.7% | ||
| Q4 24 | — | -98.6% | ||
| Q3 24 | — | -132.0% | ||
| Q2 24 | — | -139.2% |
| Q1 26 | — | -92.6% | ||
| Q4 25 | 10.2% | -83.0% | ||
| Q3 25 | 11.7% | -103.1% | ||
| Q2 25 | -64.1% | -96.1% | ||
| Q1 25 | 89.9% | -151.4% | ||
| Q4 24 | 2.6% | -103.6% | ||
| Q3 24 | 0.0% | -131.2% | ||
| Q2 24 | -3.9% | -110.9% |
| Q1 26 | — | $-0.83 | ||
| Q4 25 | $-0.05 | $-0.73 | ||
| Q3 25 | $-0.11 | $-0.82 | ||
| Q2 25 | $-0.38 | $-0.75 | ||
| Q1 25 | $0.25 | $-0.81 | ||
| Q4 24 | $-0.15 | $-0.71 | ||
| Q3 24 | $-0.16 | $-0.73 | ||
| Q2 24 | $-0.19 | $-0.55 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | — | $340.6M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $688.3M | $122.9M |
| Total Assets | $1.2B | $442.3M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $340.6M | ||
| Q4 25 | $27.2M | $388.9M | ||
| Q3 25 | $11.3M | $416.1M | ||
| Q2 25 | $30.5M | $291.0M | ||
| Q1 25 | $42.9M | $314.5M | ||
| Q4 24 | $18.3M | $320.6M | ||
| Q3 24 | $13.2M | $298.4M | ||
| Q2 24 | $49.8M | $319.1M |
| Q1 26 | — | — | ||
| Q4 25 | $473.6M | — | ||
| Q3 25 | $480.4M | — | ||
| Q2 25 | $496.4M | — | ||
| Q1 25 | $498.8M | — | ||
| Q4 24 | $527.5M | — | ||
| Q3 24 | $530.7M | — | ||
| Q2 24 | $549.4M | — |
| Q1 26 | $688.3M | $122.9M | ||
| Q4 25 | $670.3M | $139.1M | ||
| Q3 25 | $661.8M | $148.8M | ||
| Q2 25 | $670.1M | $-11.9M | ||
| Q1 25 | $689.9M | $18.9M | ||
| Q4 24 | $687.2M | $21.7M | ||
| Q3 24 | $691.2M | $11.2M | ||
| Q2 24 | $708.5M | $39.3M |
| Q1 26 | $1.2B | $442.3M | ||
| Q4 25 | $1.2B | $480.2M | ||
| Q3 25 | $1.2B | $506.9M | ||
| Q2 25 | $1.3B | $372.7M | ||
| Q1 25 | $1.3B | $386.7M | ||
| Q4 24 | $1.3B | $392.3M | ||
| Q3 24 | $1.3B | $363.6M | ||
| Q2 24 | $1.4B | $381.8M |
| Q1 26 | — | — | ||
| Q4 25 | 0.71× | — | ||
| Q3 25 | 0.73× | — | ||
| Q2 25 | 0.74× | — | ||
| Q1 25 | 0.72× | — | ||
| Q4 24 | 0.77× | — | ||
| Q3 24 | 0.77× | — | ||
| Q2 24 | 0.78× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
